Takeda and TiGenix Announce Publication in The Lancet of 24Week Results of the Phase 3 ADMIRECD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Osaka Japan August 2 2016 and Leuven Belgium August 2 2016 – Takeda Pharmaceutical Company Limited TSE 4502 “Takeda” and TiGenix NV Euronext Brussels TIG “TiGenix” today announced that the 24week results o...